Deutsche Bank reaffirmed their buy rating on shares of Prothena (NASDAQ:PRTA) in a research report sent to investors on Tuesday morning. Deutsche Bank currently has a $16.00 price target on the biotechnology company’s stock, down from their prior price target of $78.00.

Several other brokerages have also recently commented on PRTA. ValuEngine raised shares of Prothena from a sell rating to a hold rating in a report on Wednesday, April 4th. Barclays lowered their target price on shares of Prothena from $70.00 to $50.00 and set an overweight rating on the stock in a report on Thursday, April 5th. BidaskClub raised shares of Prothena from a strong sell rating to a sell rating in a report on Thursday, January 11th. Cantor Fitzgerald reaffirmed a buy rating and set a $65.00 target price on shares of Prothena in a report on Sunday, February 4th. Finally, Zacks Investment Research raised shares of Prothena from a hold rating to a buy rating and set a $43.00 price objective on the stock in a research note on Tuesday, April 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. Prothena presently has a consensus rating of Hold and a consensus price target of $53.92.

Shares of PRTA opened at $12.11 on Tuesday. Prothena has a 12 month low of $10.43 and a 12 month high of $70.00. The company has a market cap of $423.82, a PE ratio of -2.98 and a beta of 2.70.

Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.48) by $0.24. Prothena had a negative net margin of 556.84% and a negative return on equity of 33.37%. The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.27 million. During the same period last year, the firm earned ($1.41) earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. research analysts predict that Prothena will post -4.27 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in PRTA. HBK Investments L P bought a new position in Prothena in the fourth quarter valued at approximately $213,000. Jefferies Group LLC bought a new position in Prothena in the fourth quarter valued at approximately $292,000. Capital Fund Management S.A. bought a new position in Prothena in the fourth quarter valued at approximately $330,000. Millennium Management LLC bought a new position in Prothena in the fourth quarter valued at approximately $338,000. Finally, Virtus Fund Advisers LLC bought a new position in Prothena in the fourth quarter valued at approximately $358,000.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.